Methyl-CpG-binding domain protein 2 (MBD2)

Methyl-CpG-binding domain protein 2 (MBD2) is a member of the MBD family of proteins characterized by the presence of a methyl-CpG-binding domain[1][2][5]. MBD2 binds to methylated CpG dinucleotides in DNA and generally acts as a transcriptional repressor, often by recruiting the NuRD (nucleosome remodeling and histone deacetylation) complex to methylated promoters, leading to chromatin remodeling and gene silencing[1][2][4]. The protein is widely expressed, with multiple isoforms (MBD2a, MBD2b, MBD2c) that have distinct domain structures and binding properties; the major isoforms interact with corepressors via a C-terminal transcriptional repression domain[1][2]. MBD2 has roles in development, stem cell pluripotency, immune cell function, and tumorigenesis[1][2][4]. Because MBD2 is key in propagating DNA methylation-dependent transcriptional repression, it is implicated as a therapeutic target in cancer and other diseases where epigenetic silencing is maladaptive[1][2]. There are currently no approved drugs directly targeting MBD2, but disruption of its activity is under study as a way to reactivate silenced genes, notably tumor suppressors, in cancer therapy[1][2][4].

Other names

DemethylaseDMTaseNY-CO-41Methyl-CpG binding domain protein 2Methyl-CpG-binding protein MBD2methyl-CpG-binding domain protein 2, demethylase

Inhibitors may block MBD2-DNA interaction or disrupt NuRD complex recruitment, reducing methylation-dependent gene repression